title: The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers.
abstract: Currently there is no curative treatment for metastatic clear cell renal cell cancer, the commonest variant of the disease. A key factor in this treatment resistance is thought to be the molecular complexity of the disease. Targeted therapy such as the tyrosine kinase inhibitor (TKI)-sunitinib have been utilized, but only 40% of patients will respond, with the overwhelming majority of these patients relapsing within 1 year. As such the question of intrinsic and acquired resistance in renal cell cancer patients is highly relevant. In order to study resistance to TKIs, with the ultimate goal of developing effective, personalized treatments, sequential tissue after a specific period of targeted therapy is required, an approach which had proved successful in chronic myeloid leukaemia. However the application of such a strategy in renal cell carcinoma is complicated by the high level of both inter- and intratumoral heterogeneity, which is a feature of renal cell carcinoma as well as other solid tumors. Intertumoral heterogeneity due to transcriptomic and genetic differences is well established even in patients with similar presentation, stage and grade of tumor. In addition it is clear that there is great morphological (intratumoral) heterogeneity in RCC, which is likely to represent even greater molecular heterogeneity. Detailed mapping and categorization of RCC tumors by combined morphological analysis and Fuhrman grading allows the selection of representative areas for proteomic analysis. Protein based analysis of RCC is attractive due to its widespread availability in pathology laboratories; however, its application can be problematic due to the limited availability of specific antibodies. Due to the dot blot nature of the Reverse Phase Protein Arrays (RPPA), antibody specificity must be pre-validated; as such strict quality control of antibodies used is of paramount importance. Despite this limitation the dot blot format does allow assay miniaturization, allowing for the printing of hundreds of samples onto a single nitrocellulose slide. Printed slides can then be analyzed in a similar fashion to Western analysis with the use of target specific primary antibodies and fluorescently labelled secondary antibodies, allowing for multiplexing. Differential protein expression across all the samples on a slide can then be analyzed simultaneously by comparing the relative level of fluorescence in a more cost-effective and high-throughput manner.
authors: Edinburgh Urological Cancer Group, University of Edinburgh. fomahony@staffmail.ed.ac.uk
authors: Fiach C
authors: FC
authors: O'Mahony
authors: Jyoti
authors: J
authors: Nanda
authors: Alexander
authors: A
authors: Laird
authors: Peter
authors: P
authors: Mullen
authors: Helen
authors: H
authors: Caldwell
authors: Ian M
authors: IM
authors: Overton
authors: Lel
authors: L
authors: Eory
authors: Marie
authors: M
authors: O'Donnell
authors: Dana
authors: D
authors: Faratian
authors: Thomas
authors: T
authors: Powles
authors: David J
authors: DJ
authors: Harrison
authors: Grant D
authors: GD
authors: Stewart
mesh_terms: D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D040081:Protein Array Analysis / Q000379:methods*
chemical_list: D009363:Neoplasm Proteins
references: Proteome Sci. 2011 Sep 15;9:53
references: 21917185
references: J Clin Oncol. 2008 Aug 1;26(22):3743-8
references: 18669461
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: Nat Rev Urol. 2011 May;8(5):255-65
references: 21487387
references: Front Oncol. 2012 May 18;2:49
references: 22655275
references: Nat Protoc. 2008;3(11):1796-808
references: 18974738
references: Genome Med. 2010 Aug 11;2(8):53
references: 20701793
references: Bioinformatics. 2007 Aug 1;23(15):1986-94
references: 17599930
references: Blood. 2007 Dec 1;110(12):4005-11
references: 17785585
references: PLoS One. 2012;7(2):e31557
references: 22363672
references: Nature. 2010 Oct 28;467(7319):1114-7
references: 20981102